You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Monitoring System For Vector-Based Influenza Vaccine

    SBC: INDEVR, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): This Phase II Advanced Technology SBIR [PA-06-134] proposal is in response to NIAID's Notice of High-Priority Influenza Research Areas [NOT-AI-05-013]. In order to provide health officials with the tools required to eff iciently combat a pandemic strain of influenza, it is essential that rapid and cost-effective methods for vaccine production be developed. The ...

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  2. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: LEUKOGENE THERAPEUTICS INC            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Long-acting Growth Hormone for Treating HIV-Associated Adipose Redistribution Syn

    SBC: BOLDER BIOTECHNOLOGY INC            Topic: N/A

    DESCRIPTION (provided by applicant): HIV-associated adipose redistribution syndrome (HARS), a form of lipodystrophy, is a common problem in HIV patients on highly active antiretroviral therapy and occurs as a side-effect of their anti-viral drug therapies. HARS is characterized by an increase in visceral adipose tissue, dyslipidemia, and insulin insensitivity, all of which are believed to increas ...

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  4. Large-aperture Electrically Tunable Lenses with 40 Microsecond Hysteresis-free response for Remote Focusing

    SBC: BOULDER NONLINEAR SYSTEMS, INC.            Topic: 101

    PROJECT SUMMARY This Phase II Lab-to-Marketplace proposal aims to commercialize a new remote focusing technique that can change the focus of a microscope by as much as 500 μm in less than 40 μs, 3 orders of magnitude faster than other discrete focus change techniques. Our initial market is neuroscience imaging, where the ability of researchers to step between focal planes at the millisecond time ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. An add-on microscopy module for fast volumetric imaging

    SBC: MEADOWLARK OPTICS, INC.            Topic: 101

    Project Summary Microscopy with spatial light modulatorsSLMsenables use of optical techniques to simultaneously monitor and manipulate the activity of neuronal ensemblesin vitro and in vivoAs a result of successful worldwide research in this fieldsuppliers of commercial two photon microscopes feel there is extensive product potentialAs suchthree commercial microscope suppliers have licensed patent ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Long Acting Beta Interferon for Treating Multiple Sclerosis- Phase II Continuing

    SBC: BOLDER BIOTECHNOLOGY INC            Topic: N/A

    Location 2945 Wilderness Place BOULDER, CO 80301 United States 2R44NS040205-04 $1 617 340.00 2 008 Long Acting Beta Interferon for Treating Multiple Sclerosis- Phase II Continuing Department of Health and Human Services National Institutes of Health SBIR ...

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  7. Anti-fibrotic Coatings for Rapidly Exchangeable Bioprosthetic Heart Valve

    SBC: VALVEXCHANGE, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Each year, over 100,000 patients in the United States need to have their diseased heart valves replaced with artificial devices. Although bioprostheses, valves made from animal tissues, are considered ideal for most pat ients, they wear out in about 15 years. They are thus used primarily in the elderly patient who is not expected to outlive the valve. Younger p ...

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  8. Novel therapeutic approach in treatment of glioblastoma using sustained delivery of Connxin43 carboxy-terminal peptide encapsulated in biodegradable nanoparticles in combination with temozolomide

    SBC: FirstString Research, Inc            Topic: 102

    PROJECT SUMMARY Glioblastoma (GBM) is an incurable cancer even with aggressive therapies such as surgical resection followed by radiotherapy and chemotherapy using temozolomide (TMZ). Efforts to improve surgical resection or the efficacy of irradiation are limited by the potential damage these interventions cause to the brain. In contrast, sensitizing GBM to TMZ is an appealing strategy because TM ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Administrative Supplement to Promote Diversity in Research and Development Small Businesses

    SBC: NEUROENE THERAPEUTICS INC            Topic: NINDS

    Abstract Neuroene Therapeutics is a biotech company established to develop and commercialize safe effective therapies for epilepsyinpeople develop epilepsy in their lifetimehowever the currently available anti epileptic drugsAEDshave several issues and liabilities that leave unmet market needssuch asnot controlling seizures forof patients with epilepsycurrent AEDs only treat the symptoms of epilep ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Proprietary biologic treatment to heal skin wounds

    SBC: Allander Biotechnologies            Topic: NIDCR

    SUMMARY Chronic skin wounds associated with various diseasese gdiabetesand aberrant healing from acute woundinge ghypertrophic scarringare a major health care burdenThis health burden increases in aging populationsThe cost to treat these conditions exceeds $billion annuallyCurrentlyREGRANEXa cream containing a biologic based on human PDGFPlatelet Derived Growth Factoris the only FDAFood and Drug A ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government